Business Context and Reporting Period
This Form 6-K filing by Novartis AG, dated December 5, 2019, reports the commencement of a cash tender offer to acquire The Medicines Company (NASDAQ: MDCO). The filing serves as a notification of the tender offer rather than a periodic financial report.
Key Financial Metrics
The filing does not provide Novartis AG's consolidated revenue, profit, cash flow, margins, debt, or liquidity metrics for the reporting period. The only specific financial figure disclosed relates to the acquisition terms:
- Offer Price: USD 85.00 per share of The Medicines Company common stock.
- Payment Terms: Cash, net to the seller, without interest, subject to tax withholding.
- Financing Condition: The offer is not subject to a financing condition.
Material Changes
There are no material changes to Novartis's historical financial performance reported in this document. The material event is the initiation of the acquisition process for The Medicines Company, pursuant to a Merger Agreement dated November 23, 2019.
Guidance, Outlook, Risks, and Contingencies
Transaction Timeline: The tender offer is scheduled to expire at 12:00 midnight, New York City time, on January 3, 2020, unless extended.
Closing Conditions: The transaction is subject to customary conditions, including:
- Tender of at least a majority of The Medicines Company's outstanding shares.
- Expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.
Risks and Uncertainties: The filing includes extensive forward-looking statements and disclaimers. Key risks include:
- Failure to meet closing conditions (e.g., insufficient share tender).
- Regulatory delays or actions regarding the acquisition or the development of The Medicines Company's product, inclisiran.
- Uncertainty regarding the commercialization and regulatory approval of inclisiran.
- Integration challenges and the potential failure to realize expected synergies.
- Legal proceedings and intellectual property risks.
Investor Verification Checklist
- Verify the final terms and conditions in the Tender Offer Statement on Schedule TO filed with the SEC.
- Confirm the recommendation of The Medicines Company's board of directors in the Schedule 14D-9 filing.
- Monitor the tendering volume to ensure the majority ownership threshold is met.
- Track regulatory approval status under the Hart-Scott-Rodino Act.
- Review the development and regulatory status of inclisiran, the primary asset of the target company.